Parenteral anticoagulants in heart disease: current status and perspectives (Section II). Position paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease.

@article{deCaterina2013ParenteralAI,
  title={Parenteral anticoagulants in heart disease: current status and perspectives (Section II). Position paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease.},
  author={Raffaele de Caterina and Steen Elkjaer Husted and Lars Wallentin and Felicita Andreotti and Harald Arnesen and Fedor Bachmann and Colin Baigent and Kurt Huber and J{\o}rgen Jespersen and Steen Dalby Kristensen and Gregory Y. H. Lip and Jo{\~a}o Morais and Lars Hvilsted Rasmussen and Agneta Siegbahn and Freek W.A. Verheugt and Jeffrey I. Weitz},
  journal={Thrombosis and haemostasis},
  year={2013},
  volume={109 5},
  pages={
          769-86
        }
}
Anticoagulants are a mainstay of cardiovascular therapy, and parenteral anticoagulants have widespread use in cardiology, especially in acute situations. Parenteral anticoagulants include unfractionated heparin, low-molecular-weight heparins, the synthetic pentasaccharides fondaparinux, idraparinux and idrabiotaparinux, and parenteral direct thrombin inhibitors. The several shortcomings of unfractionated heparin and of low-molecular-weight heparins have prompted the development of the other… 
View on PubMed
escardio.org
252 Citations
Highly Influential Citations
2
Background Citations
20
Methods Citations
2

252 Citations

Citation Type

Citation Type

Oral anticoagulants in coronary heart disease (Section IV). Position paper of the ESC Working Group on Thrombosis - Task Force on Anticoagulants in Heart Disease.
TLDR
The role for the NOACs in ACS management is therefore complicated, because it is uncertain how they compare with newer antiplatelet agents, such as prasugrel, ticagrelor or vorapaxar, and because their safety in combination with these other drugs is unknown.
Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease.
TLDR
The mechanisms of action, pharmacological properties and side effects of VKAs, which are used in the management of cardiovascular diseases, including coronary heart disease, stroke prevention in atrial fibrillation, heart valves and/or chronic heart failure, are reviewed.
Evolving Treatments for Arterial and Venous Thrombosis: Role of the Direct Oral Anticoagulants.
TLDR
The pharmacology of the direct oral anticoagulants is reviewed and the advantages of the DOACs over vitamin K antagonists are described, as well as highlighting current challenges and limitations, and identifying future directions for antICOagulant therapy.
Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays
Traditional anticoagulant agents such as vitamin K antagonists (VKAs), unfractionated heparin (UFH), low molecular weight heparins (LMWHs) and fondaparinux have been widely used in the prevention and…
The role of oral anticoagulant therapy in patients with acute coronary syndrome
TLDR
The present article provides an overview of the rationale and prognostic role of oral anticoagulant therapy in ACS patients as well as recent updated clinical data, in particular with NOACs, in the field and future perspectives on this topic.
Organ-specific bleeding patterns of anticoagulant therapy: lessons from clinical trials.
TLDR
The results of recent large-scale randomised controlled trials comparing NOACs with VKAs for the prevention of stroke in patients with non-valvular atrial fibrillation have produced some unexpected results, including a reduced risk of major bleeding.
Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association
TLDR
Effective stroke prevention (which is essentially OAC) can then be offered to AF patients with ≥1 stroke risk factor(s), with treatment decisions made in consultation with patients and incorporating their preferences.
Antithrombotic management in patients undergoing electrophysiological procedures: a European Heart Rhythm Association (EHRA) position document endorsed by the ESC Working Group Thrombosis, Heart Rhythm Society (HRS), and Asia Pacific Heart Rhythm Society (APHRS).
  • C. Sticherling, F. Marín, +12 authors G. Lip
  • Medicine
    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology
  • 2015
TLDR
The present document covers the antithrombotic management during different ablation procedures, implantation or exchange of cardiac implantable electronical devices (CIEDs), as well as the management of peri-interventional bleeding complications.
Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1.
TLDR
A review of analyses of subgroups of patients from trials of vitamin K antagonists vs. NOACs for stroke prevention in AF with the aim to identify patient groups who might benefit from a particular OAC more than from another.
New Approaches to the Role of Thrombin in Acute Coronary Syndromes: Quo Vadis Bivalirudin, a Direct Thrombin Inhibitor?
TLDR
The aim of this review is to update the development of bivalirudin, including pharmacological properties, obtained information from clinical trials evaluating efficacy and safety of bivalsurudin in ACS; as well as the recommendations of clinical Guidelines.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 293 REFERENCES
New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper.
Anticoagulants in heart disease: current status and perspectives.
TLDR
This document is intended to follow-up on the Task Force Document on the use of antiplatelet agents in cardiovascular disease, proposed by the committee of experts appointed similarly by the ESC Working Group on Thrombosis and is expected to be regularly updated.
Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
TLDR
Three additional parenteral direct thrombin inhibitors and danaparoid are approved as alternatives to heparin in patients with HIT, and fondaparinux-associated HIT or osteoporosis is unlikely to occur.
Update on fondaparinux: role in management of thromboembolic and acute coronary events.
TLDR
The available literature is reviewed that provides evidence for the efficacy of fondaprinux in management of thromboembolic disease as well as acute coronary syndromes.
Antithrombotic strategies in non-ST elevation acute coronary syndromes: focus on bivalirudin.
TLDR
Bivalirudin has several notable mechanistic advantages compared with unfractionated heparin, including activity against clot-bound thrombin, inhibition ofThrombin-induced platelet activation, short plasma half-life in patients with normal or mildly impaired renal function, and linear pharmacokinetics less affected by plasma proteins and renal insufficiency.
A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
TLDR
Antithrombotic therapy with enoxaparin plus aspirin was more effective than unfractionated heparin plus aspirin in reducing the incidence of ischemic events in patients with unstable angina or non-Q-wave myocardial infarction in the early phase.
The Warfarin and Antiplatelet Therapy in Heart Failure trial (WATCH): rationale, design, and baseline patient characteristics.
Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis
Safety and Efficacy of Enoxaparin Compared With Unfractionated Heparin and Oral Anticoagulants for Prevention of Thromboembolic Complications in Cardioversion of Nonvalvular Atrial Fibrillation: The Anticoagulation in Cardioversion using Enoxaparin (ACE) Trial
TLDR
Enoxaparin is noninferior to UFH+phenprocoumon for prevention of ischemic and embolic events, bleeding complications, and death in TEE-guided cardioversion of atrial fibrillation and may make it the preferred drug for initiation of anticoagulation in this setting.
Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group.
  • Medicine
    Lancet
  • 1996
TLDR
It is recommended that treatment with a combination of dalteparin and aspirin for at least 6 days should be considered in patients with unstable CAD to reduce the risk of new cardiac events and to allow time for risk stratification and selection of a long-term treatment strategy.
...
1
2
3
4
5
...